Glacier Peak Capital LLC purchased a new stake in Bristol-Myers Squibb Co (NYSE:BMY) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 20,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,265,000.
A number of other large investors also recently made changes to their positions in the business. W.G. Shaheen & Associates DBA Whitney & Co acquired a new position in shares of Bristol-Myers Squibb during the 1st quarter worth approximately $101,000. Institutional & Family Asset Management LLC acquired a new position in shares of Bristol-Myers Squibb during the 1st quarter worth approximately $106,000. Delphi Private Advisors LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $108,000. Centerpoint Advisors LLC raised its stake in shares of Bristol-Myers Squibb by 373.1% during the 1st quarter. Centerpoint Advisors LLC now owns 1,774 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,399 shares during the period. Finally, NuWave Investment Management LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $119,000. 71.37% of the stock is owned by institutional investors.
Several research analysts have recently weighed in on BMY shares. Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Tuesday, April 17th. Argus reaffirmed a “buy” rating and set a $66.43 target price (down from $75.00) on shares of Bristol-Myers Squibb in a research note on Wednesday, March 21st. BMO Capital Markets dropped their price target on Bristol-Myers Squibb from $51.00 to $47.00 and set an “underperform” rating for the company in a research report on Wednesday, April 18th. JPMorgan Chase & Co. set a $75.00 price target on Bristol-Myers Squibb and gave the stock an “overweight” rating in a research report on Tuesday, March 20th. Finally, Morgan Stanley upgraded Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $51.56 to $78.00 in a research report on Thursday, February 15th. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and seven have assigned a buy rating to the stock. Bristol-Myers Squibb has an average rating of “Hold” and a consensus price target of $62.84.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.09. The company had revenue of $5.19 billion during the quarter, compared to analysts’ expectations of $5.25 billion. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.84 EPS. equities analysts anticipate that Bristol-Myers Squibb Co will post 3.43 earnings per share for the current year.
In related news, Director Dinesh C. Paliwal bought 4,770 shares of the company’s stock in a transaction on Monday, April 30th. The stock was bought at an average cost of $52.40 per share, for a total transaction of $249,948.00. Following the acquisition, the director now directly owns 8,027 shares in the company, valued at $420,614.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.12% of the stock is owned by corporate insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.